Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Y
- Development stage
- Preclinical
- Lead developer
- Eisai
- Modality
- Small Molecules
01
Overview
Compound Y is a 6-5 fused ring heterocyclic derivative originally designed by Eisai for anticancer research. It acts as a dihydrofolate reductase (DHFR) inhibitor. In preclinical studies, Compound Y has demonstrated selective, broad-spectrum in vitro antiprotozoal activity against *Leishmania donovani*, *Plasmodium falciparum*, and *Trypanosoma brucei*, making it a potential candidate for repurposing against malaria, leishmaniasis, and African trypanosomiasis.
02
Targets
DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on Compound Y.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Compound Y.